[{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tilvestamab","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||AXL","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BerGenBio ASA \/ BerGenBio ASA","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio ASA \/ BerGenBio ASA"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Meteva AS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Meteva AS","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Meteva AS"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"University Hospital Southampton","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ University Hospital Southampton","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ University Hospital Southampton"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Tempus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Tempus","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Tempus"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"University Of Alabama","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ University Of Alabama","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio ASA \/ University Of Alabama"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Oncoinvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BerGenBio ASA \/ Oncoinvent","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Oncoinvent"}]
Find Clinical Drug Pipeline Developments & Deals by BerGenBio ASA
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
